J M Woolderink1, G H De Bock2, J A de Hullu3, H Hollema4, R P Zweemer5, B F M Slangen6, K N Gaarenstroom7, M van Beurden8, H C van Doorn9, R H Sijmons10, H F A Vasen11, M J E Mourits12. 1. Department of Gynecology, Martini Hospital Groningen, The Netherlands; Department of Gynecologic Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Electronic address: j.m.woolderink@umcg.nl. 2. Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 3. Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands. 4. Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 5. Department Gynecological Oncology, UMC Utrecht Cancer Center, Utrecht, The Netherlands. 6. Department of Obstetrics and Gynecology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands. 7. Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands. 8. Department of Gynecology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 9. Department of Gynecology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 10. Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 11. Department of Gastroenterology & Hepatology, Leiden University Medical Center, Leiden, The Netherlands. 12. Department of Gynecologic Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Abstract
OBJECTIVE: To describe clinical characteristics of Lynch syndrome associated ovarian cancer and the efficacy of surveillance in the early detection of these ovarian cancers. METHODS: All Lynch syndrome associated ovarian cancer cases identified in either the Dutch Lynch syndrome registry (DLSR) between 1987 and 2016, and/or the cohort at the University Medical Center Groningen (UMCG) between 1993 and 2016 were included. Clinical data on age at diagnosis, mutation type, histological type, FIGO stage, treatment, follow-up and gynecological surveillance were collected. RESULTS: A total of 46/798 (6%) women in the DLSR and 7/80 (9%) in the UMCG cohort were identified as LS associated ovarian cancer patients. The median age at ovarian cancer diagnosis was 46.0 years (range 20-75 years). The most frequently reported histological type was endometrioid adenocarcinoma (40%; n = 21) and serous carcinoma (36%; n = 19). Most tumors (87%; n = 46) were detected at an early stage (FIGO I/II). Forty-one of 53 (77%) patients were diagnosed with ovarian cancer before LS was diagnosed. In the other 12/53 (23%) women, ovarian cancer developed after starting annual gynecological surveillance for LS; three ovarian cancers were screen-detected in asymptomatic women. Overall survival was 83%. CONCLUSION: Ovarian cancer in women with LS has a wide age-range of onset, is usually diagnosed at an early stage with predominantly endometrioid type histology and a good overall survival. The early stage at diagnosis could not be attributed to annual gynecological surveillance.
OBJECTIVE: To describe clinical characteristics of Lynch syndrome associated ovarian cancer and the efficacy of surveillance in the early detection of these ovarian cancers. METHODS: All Lynch syndrome associated ovarian cancer cases identified in either the Dutch Lynch syndrome registry (DLSR) between 1987 and 2016, and/or the cohort at the University Medical Center Groningen (UMCG) between 1993 and 2016 were included. Clinical data on age at diagnosis, mutation type, histological type, FIGO stage, treatment, follow-up and gynecological surveillance were collected. RESULTS: A total of 46/798 (6%) women in the DLSR and 7/80 (9%) in the UMCG cohort were identified as LS associated ovarian cancerpatients. The median age at ovarian cancer diagnosis was 46.0 years (range 20-75 years). The most frequently reported histological type was endometrioid adenocarcinoma (40%; n = 21) and serous carcinoma (36%; n = 19). Most tumors (87%; n = 46) were detected at an early stage (FIGO I/II). Forty-one of 53 (77%) patients were diagnosed with ovarian cancer before LS was diagnosed. In the other 12/53 (23%) women, ovarian cancer developed after starting annual gynecological surveillance for LS; three ovarian cancers were screen-detected in asymptomatic women. Overall survival was 83%. CONCLUSION:Ovarian cancer in women with LS has a wide age-range of onset, is usually diagnosed at an early stage with predominantly endometrioid type histology and a good overall survival. The early stage at diagnosis could not be attributed to annual gynecological surveillance.
Authors: Soyoun Rachel Kim; Alicia Tone; Raymond H Kim; Matthew Cesari; Blaise A Clarke; Lua Eiriksson; Tae Hart; Melyssa Aronson; Spring Holter; Alice Lytwyn; Manjula Maganti; Leslie Oldfield; Steven Gallinger; Marcus Q Bernardini; Amit M Oza; Bojana Djordjevic; Jordan Lerner-Ellis; Emily Van de Laar; Danielle Vicus; Trevor J Pugh; Aaron Pollett; Sarah E Ferguson Journal: Cancer Date: 2020-08-18 Impact factor: 6.860